A detailed history of Oppenheimer Asset Management Inc. transactions in Biogen Inc. stock. As of the latest transaction made, Oppenheimer Asset Management Inc. holds 33,980 shares of BIIB stock, worth $7.78 Million. This represents 0.11% of its overall portfolio holdings.

Number of Shares
33,980
Previous 38,599 11.97%
Holding current value
$7.78 Million
Previous $9.99 Million 26.64%
% of portfolio
0.11%
Previous 0.14%

Shares

26 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 06, 2024

SELL
$212.02 - $267.71 $979,320 - $1.24 Million
-4,619 Reduced 11.97%
33,980 $7.33 Million
Q4 2023

Feb 13, 2024

SELL
$222.59 - $267.94 $622,361 - $749,160
-2,796 Reduced 6.75%
38,599 $9.99 Million
Q3 2023

Nov 07, 2023

BUY
$253.3 - $285.89 $31,155 - $35,164
123 Added 0.3%
41,395 $10.6 Million
Q2 2023

Aug 02, 2023

SELL
$275.25 - $318.06 $112,852 - $130,404
-410 Reduced 0.98%
41,272 $11.8 Million
Q1 2023

May 10, 2023

SELL
$256.56 - $292.34 $126,740 - $144,415
-494 Reduced 1.17%
41,682 $11.6 Million
Q4 2022

Feb 06, 2023

SELL
$252.44 - $306.72 $1.27 Million - $1.54 Million
-5,023 Reduced 10.64%
42,176 $11.7 Million
Q3 2022

Nov 14, 2022

BUY
$194.69 - $268.46 $273,928 - $377,723
1,407 Added 3.07%
47,199 $12.6 Million
Q2 2022

Aug 08, 2022

SELL
$187.54 - $223.02 $11,439 - $13,604
-61 Reduced 0.13%
45,792 $9.34 Million
Q1 2022

May 12, 2022

BUY
$193.77 - $244.14 $53,286 - $67,138
275 Added 0.6%
45,853 $9.66 Million
Q4 2021

Feb 02, 2022

SELL
$223.92 - $287.77 $1.56 Million - $2 Million
-6,960 Reduced 13.25%
45,578 $10.9 Million
Q3 2021

Nov 12, 2021

BUY
$282.99 - $369.05 $728,699 - $950,303
2,575 Added 5.15%
52,538 $14.9 Million
Q2 2021

Aug 03, 2021

BUY
$259.0 - $414.71 $939,134 - $1.5 Million
3,626 Added 7.83%
49,963 $17.3 Million
Q1 2021

May 17, 2021

BUY
$242.95 - $284.63 $626,082 - $733,491
2,577 Added 5.89%
46,337 $13 Million
Q4 2020

Feb 11, 2021

BUY
$236.26 - $355.63 $798,558 - $1.2 Million
3,380 Added 8.37%
43,760 $10.7 Million
Q3 2020

Nov 13, 2020

BUY
$264.77 - $305.71 $533,511 - $616,005
2,015 Added 5.25%
40,380 $11.5 Million
Q2 2020

Aug 11, 2020

BUY
$258.66 - $342.55 $1.27 Million - $1.68 Million
4,907 Added 14.67%
38,365 $10.3 Million
Q1 2020

May 08, 2020

BUY
$268.85 - $341.04 $705,193 - $894,547
2,623 Added 8.51%
33,458 $10.6 Million
Q4 2019

Feb 07, 2020

BUY
$220.06 - $304.07 $62,717 - $86,659
285 Added 0.93%
30,835 $9.15 Million
Q3 2019

Oct 31, 2019

BUY
$217.44 - $243.88 $585,565 - $656,768
2,693 Added 9.67%
30,550 $7.11 Million
Q2 2019

Aug 09, 2019

BUY
$219.29 - $241.72 $1.21 Million - $1.34 Million
5,526 Added 24.75%
27,857 $6.52 Million
Q1 2019

Apr 24, 2019

BUY
$216.71 - $338.96 $635,393 - $993,830
2,932 Added 15.11%
22,331 $5.28 Million
Q4 2018

Jan 30, 2019

BUY
$278.5 - $352.75 $193,557 - $245,161
695 Added 3.72%
19,399 $5.84 Million
Q3 2018

Oct 26, 2018

SELL
$293.51 - $383.83 $387,726 - $507,039
-1,321 Reduced 6.6%
18,704 $6.61 Million
Q2 2018

Aug 10, 2018

BUY
$257.52 - $306.91 $694,531 - $827,736
2,697 Added 15.56%
20,025 $5.81 Million
Q1 2018

May 09, 2018

BUY
$260.13 - $367.91 $645,902 - $913,520
2,483 Added 16.73%
17,328 $4.75 Million
Q3 2017

Nov 14, 2017

BUY
$281.15 - $329.69 $4.17 Million - $4.89 Million
14,845
14,845 $4.65 Million

Others Institutions Holding BIIB

About BIOGEN INC.


  • Ticker BIIB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 144,000,992
  • Market Cap $33B
  • Description
  • Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...
More about BIIB
Track This Portfolio

Track Oppenheimer Asset Management Inc. Portfolio

Follow Oppenheimer Asset Management Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Oppenheimer Asset Management Inc., based on Form 13F filings with the SEC.

News

Stay updated on Oppenheimer Asset Management Inc. with notifications on news.